Tizanidine trandermal patch - MEDRx

Drug Profile

Tizanidine trandermal patch - MEDRx

Alternative Names: MRX-4TZT

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MEDRx
  • Class Antispastics; Benzothiazoles; Imidazolines; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Spastic paralysis

Most Recent Events

  • 16 May 2017 Chemical structure information added
  • 06 Apr 2017 Cipla USA enters into a worldwide licensing agreement (except East Asia) with MEDRx to develop and commercialise tizanidine transdermal patch for Spastic paralysis
  • 06 Apr 2017 MEDRx completes a phase I trial Spastic paralysis in USA (Transdermal) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top